Industry News
Biotechnology Industry News
Scholar Rock in a hard place as biotech lays off 25% of staff, narrows pipeline and loses CMO
Scholar Rock in a hard place as biotech lays off 25% of staff, narrows pipeline and loses CMO jwaldron Tue, 05/17/2022 - 09:15
Aiming to be biggest biotech in Boston, Vertex plots 500-person cell, gene therapy R&D center
Aiming to be biggest biotech in Boston, Vertex plots 500-person cell, gene therapy R&D center ntaylor Tue, 05/17/2022 - 07:34
AstraZeneca bags pan-variant COVID-19 antibodies from stealthy biotech in $157M deal
AstraZeneca bags pan-variant COVID-19 antibodies from stealthy biotech in $157M deal ntaylor Tue, 05/17/2022 - 06:06
Remix closes $70M funding with pipeline ‘really humming,’ but to what tune?
Remix closes $70M funding with pipeline 'really humming,' but to what tune? mbayer Mon, 05/16/2022 - 16:24
After 14 years, Agios is looking for a partner to tango with, but tough changes lie ahead
After 14 years, Agios is looking for a partner to tango with, but tough changes lie ahead aarmstrong Mon, 05/16/2022 - 15:49
VC firm Sofinnova banks $1B from Apollo to invest in early-stage biotech solutions
VC firm Sofinnova banks $1B from Apollo to invest in early-stage biotech solutions gmasson Mon, 05/16/2022 - 10:39
AbbVie coughs up nearly $50M for Cugene’s autoimmune med in a bid to shore up life post-Humira
AbbVie coughs up nearly $50M for Cugene's autoimmune med in a bid to shore up life post-Humira mbayer Mon, 05/16/2022 - 09:39
To TIGIT or not to TIGIT? Roche’s latest trial flop casts shadow on Big Pharma’s $6B bet
To TIGIT or not to TIGIT? Roche's latest trial flop casts shadow on Big Pharma's $6B bet jwaldron Mon, 05/16/2022 - 07:40
From Redditors to creditors: Orphazyme’s wild ride ends with $13M sale to satisfy bankruptcy court
From Redditors to creditors: Orphazyme's wild ride ends with $13M sale to satisfy bankruptcy court ntaylor Mon, 05/16/2022 - 06:07
Shionogi splashes $100M on F2G’s rare fungal disease drug to unlock new class of medicine
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine ntaylor Mon, 05/16/2022 - 05:30
Kriya cashes in $270M series C to further finance all-in-one gene therapy biz
Kriya cashes in $270M series C to further finance all-in-one gene therapy biz mbayer Sun, 05/15/2022 - 18:02
mRNA Unlocked: How Technology Convergence Is Driving the Next Wave
mRNA Unlocked: How Technology Convergence Is Driving the Next Wave jfrasor Fri, 05/13/2022 - 12:39
Update: Checkmate details bleak future if $250M Regeneron merger does not close
Update: Checkmate details bleak future if $250M Regeneron merger does not close aarmstrong Fri, 05/13/2022 - 11:16
Adagio still hopes to build omicron offense for lead COVID-19 therapy
Adagio still hopes to build omicron offense for lead COVID-19 therapy aarmstrong Fri, 05/13/2022 - 09:34
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal aarmstrong Fri, 05/13/2022 - 08:54
FDA tags Editas’ thalassemia cell therapy an orphan drug as it rounds final bend in race to clinic
FDA tags Editas' thalassemia cell therapy an orphan drug as it rounds final bend in race to clinic ntaylor Fri, 05/13/2022 - 07:29
Roche’s TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug
Roche's TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug ntaylor Fri, 05/13/2022 - 04:55
Chutes & Ladders—Moderna CFO Gomez departs after just one day following unearthed investigation
Chutes & Ladders—Moderna CFO Gomez departs after just one day following unearthed investigation mbayer Thu, 05/12/2022 - 13:24
Bristol Myers provides Bridge over troubled water with $905M deal to enter SHP2 race
Bristol Myers provides Bridge over troubled water with $905M deal to enter SHP2 race ntaylor Thu, 05/12/2022 - 08:58
After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhom
After 20 years, Boehringer vet hits the exit to become CEO at autoimmune biotech SciRhom ntaylor Thu, 05/12/2022 - 07:47